Sorry, I should have said Part A of the Tacti-002 trial in 1st line NSCLC trial. The data presented at the upcoming conference is PartB in 2nd line NSCLC.
The Part A data is more interesting and important, Imo. the initial data showed efficacy similar to PartC in Head and Neck which resulted in the fast track designation. The PartA data in 1st line NSCLC was the data Marc referred to as "exciting" in a recent presentation. It's been a long time since we heard anything, I think they said H1 2022, but no specifics.
This data could really move things, Imo.
Relatlimab, page-17
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.8¢ |
Change
-0.003(0.63%) |
Mkt cap ! $581.0M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 41.0¢ | 39.5¢ | $1.159M | 2.896M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 28 | 198941 | 39.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.0¢ | 159700 | 15 |
View Market Depth
| Last trade - 15.50pm 11/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |